Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status-Reference-Cited by-同舟云学术

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Published:2020-08-26 Issue:10 Volume:111 Page:3739-3746
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kano Hirohisa¹^ORCID,Ichihara Eiki²^ORCID,Harada Daijiro³,Inoue Koji⁴,Kayatani Hiroe⁵,Hosokawa Shinobu⁶,Kishino Daizo⁷,Watanabe Kazuhiko⁸,Ochi Nobuaki⁹,Oda Naohiro¹⁰,Hara Naofumi¹,Ninomiya Kiichiro¹,Hotta Katsuyuki¹¹^ORCID,Maeda Yoshinobu¹,Kiura Katsuyuki²

Affiliation:

1. Department of Hematology, Oncology, and Respiratory Medicine Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan

2. Department of Allergy and Respiratory Medicine Okayama University Hospital Okayama Japan

3. Department of Thoracic Oncology National Hospital Organization Shikoku Cancer Center Matsuyama Japan

4. Department of Respiratory Medicine Ehime Prefectural Central Hospital Matsuyama Japan

5. Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama Japan

6. Department of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama Japan

7. Department of Respiratory Medicine Himeji Red Cross Hospital Himeji Japan

8. Department of Internal Medicine Okayama Saiseikai General Hospital Okayama Japan

9. Department of General Internal Medicine 4 Kawasaki Medical School Okayama Japan

10. Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan

11. Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14590

Reference23 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

5. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis;Cancer Biology & Therapy;2024-05-30

2. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan;Frontiers in Oncology;2024-04-30

3. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer;International Journal of Cancer;2024-01-09

4. The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review;Translational Lung Cancer Research;2023-11

5. Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer;Respiratory Investigation;2023-09